查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1584121

癌症生物标记市场，按生物标记类型、癌症类型、应用、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Cancer Biomarkers Market, By Biomarker Type, By Cancer Type, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 316 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年癌症生物标记市场规模为289.2841亿美元，2024年至2032年复合年增长率为12.90%。

癌症生物标记市场-市场动态

对个人化医疗的需求不断增长推动了癌症生物标记市场的成长

对个人化医疗的需求不断增长，极大地推动了癌症生物标记市场的成长，因为它允许更有针对性和更有效的癌症治疗。美国国立卫生研究院 (NIH) 和世界卫生组织 (WHO) 等组织强调生物标记在推进精准肿瘤学方面的重要性，特别是考虑到 2020 年至 2040 年间全球癌症病例预计将增加 47%。强调BRCA1 和BRCA2 等生物标记在评估乳癌和卵巢癌风险方面发挥关键作用。此外，生物标誌物驱动的疗法越来越多地被纳入临床指南，从美国 FDA 在过去十年中批准了多种基于生物标誌物的治疗方法即可看出。这些进步正在推动癌症诊断和治疗途径的研究和创新。

癌症生物标记市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032）每年将以 12.90% 左右的复合年增长率成长

根据生物标记类型细分，预计遗传生物标记将在 2023 年显示出最大的市场份额

根据癌症类型细分，乳癌是 2023 年的主要癌症类型

按地区划分，北美是 2023 年的主要收入来源

癌症生物标记市场-細項分析：

全球癌症生物标记市场根据生物标记类型、癌症类型、应用和区域进行细分。

根据生物标记类型，市场分为四类：遗传生物标记、蛋白质生物标记、表观遗传生物标记和代谢生物标记。遗传生物标记因其在癌症诊断和个人化治疗中的关键作用而具有最高优先事项。随后出现蛋白质生物标记物，这对于监测疾病进展至关重要。表观遗传和代谢生物标记越来越重要，但在临床应用的排名略低。

根据癌症类型，市场分为两类：乳癌、肺癌、大肠癌和摄护腺癌。由于乳癌的高发生率和广泛的研究，乳癌生物标记成为重中之重。鑑于其死亡率和生物标记的进步，肺癌紧随其后。大肠直肠癌排名第三，诊断焦点不断增加，而前列腺癌生物标记在市场上的优先顺序略低。

癌症生物标记市场 - 地理洞察

在先进的医疗基础设施和精准医学的重大研发投资的推动下，北美在癌症生物标记市场占据主导地位。美国在该地区处于领先地位，美国国家癌症研究所(NCI) 资助了多项生物标记研究项目，预计2021 年将新增约190 万癌症病例。倡议已为生物标誌物分配了大量资金- 推动癌症研究，特别是在英国和德国。在亚太地区，医疗保健的快速进步和癌症盛行率的上升，特别是在中国和印度，正在推动市场成长。中国国家癌症中心报告每年新增癌症病例超过 450 万例，促使政府投资生物标记开发。拉丁美洲、中东和非洲是新兴地区，人们的认知不断提高，政府采取的措施（例如巴西国家癌症研究所）在早期诊断和生物标记采用方面的努力也不断提高。这些地理动态反映了全球癌症生物标记市场的不同焦点和发展。

癌症生物标记市场-竞争格局：

癌症生物标记市场的竞争格局高度活跃，北美由于主要参与者的存在和频繁的创新而处于领先地位。 Thermo Fisher Scientific 和 Roche Diagnostics 等公司在该地区占据主导地位，Roche 最近推出了 Elecsys(R) PD-L1 生物标记测试，增强了其肿瘤诊断产品组合。在欧洲，Qiagen 和 Bio-Rad Laboratories 是透过策略合作推动市场的主要参与者。例如，2022 年，Qiagen 与 Neuron23 合作开发神经退化性疾病的伴随诊断，将其重点扩大到基于生物标记的治疗。亚太地区的竞争日益激烈，中国华大基因等公司纷纷建立国际合作关係以利用生物标记研究。 2021 年，Quest Diagnostics 收购了总部位于印度的 Strand Life Sciences，以增强其肿瘤检测能力。拉丁美洲、中东和非洲仍在发展中，但不断增长的合作伙伴关係和投资表明人们对基于生物标誌物的癌症解决方案的兴趣日益浓厚，公司致力于扩大在这些地区的业务。

最新进展：

2024 年 8 月，Illumina 的 TruSight Oncology Excellent 测试获得 FDA 批准，成为第一个针对癌症的综合基因组分析 IVD 试剂盒。它分析了 500 多个基因，有助于为患有特定实体瘤和基因融合的患者进行标靶治疗配对。

2024 年 10 月，阿斯特捷利康计划推出生物标记驱动的疗法作为传统化疗的替代方案。该公司旨在透过专注于精准医疗、根据遗传标记和肿瘤特征针对特定癌症类型提供客製化治疗来提高患者治疗效果。

目录

第 1 章：癌症生物标记市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按生物标记类型分類的癌症生物标记市场片段
    • 按癌症类型分類的癌症生物标记市场片段
    • 癌症生物标记市场片段（按应用）
    • 按国家/地区分類的癌症生物标记市场片段
    • 按地区分類的癌症生物标记市场片段
  • 竞争洞察

第 3 章：癌症生物标记主要市场趋势

  • 癌症生物标记市场驱动因素
    • 市场驱动因素的影响分析
  • 癌症生物标记市场限制
    • 市场限制影响分析
  • 癌症生物标记市场机会
  • 癌症生物标记市场未来趋势

第 4 章：癌症生物标记产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：癌症生物标记市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：癌症生物标记市场格局

  • 2023 年癌症生物标记市场占有率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：癌症生物标记市场 - 按生物标记类型

  • 概述
    • 按生物标誌物类型分類的细分市场份额分析
    • 基因生物标记
    • 蛋白质生物标记
    • 表观遗传生物标记
    • 代谢生物标记

第 8 章：癌症生物标记市场 - 按癌症类型

  • 概述
    • 按癌症类型分類的细分市场份额分析
    • 乳癌
    • 肺癌
    • 大肠直肠癌
    • 摄护腺癌

第 9 章：癌症生物标记市场 - 按应用

  • 概述
    • 按应用分類的细分市场占有率分析
    • 诊断
    • 预后
    • 药物发现与开发
    • 个人化医疗

第 10 章：癌症生物标记市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美癌症生物标记主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按生物标记类型）
    • 北美市场规模和预测（按癌症类型）
    • 北美市场规模和预测（按应用）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲癌症生物标记主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按生物标记类型）
    • 欧洲市场规模和预测（按癌症类型）
    • 欧洲市场规模和预测（按应用）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区癌症生物标记主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按生物标记类型）
    • 亚太地区市场规模和预测（按癌症类型）
    • 亚太地区市场规模与预测（按应用）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲癌症生物标记主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模和预测（按生物标记类型）
    • 拉丁美洲市场规模与预测（按癌症类型）
    • 拉丁美洲市场规模与预测（按应用）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲癌症生物标记主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按生物标记类型）
    • 中东和非洲市场规模及预测（按癌症类型）
    • 中东和非洲市场规模及预测（按应用）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 癌症生物标记产业

  • 竞争仪表板
  • 公司简介
    • Abbott Laboratories
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.
    • Exact Sciences Corporation
    • Foundation Medicine, Inc. (Roche)
    • GE Healthcare (General Electric Company)
    • Guardant Health, Inc.
    • Hologic, Inc.
    • Illumina, Inc.
    • Myriad Genetics, Inc.
    • NeoGenomics, Inc.
    • PerkinElmer, Inc.
    • Qiagen NV
    • Roche Diagnostics (F. Hoffmann-La Roche AG)
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • Others

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4104

REPORT HIGHLIGHT

Cancer Biomarkers Market size was valued at USD 28,928.41 million in 2023, expanding at a CAGR of 12.90% from 2024 to 2032.

The Cancer Biomarkers Market refers to identifying and utilizing biological molecules that indicate the presence of cancer in the body, aiding in diagnosis, prognosis, and therapy selection. Increasing demand for personalized medicine, advances in omics technologies, and growing investments in cancer research are boosting market growth. The rising prevalence of cancer globally, with an estimated 19.3 million new cases reported in 2020, underscores the need for efficient diagnostic tools. However, the high costs of biomarker validation and stringent regulatory requirements pose challenges to market expansion. Emerging opportunities lie in developing non-invasive liquid biopsy techniques, which are gaining attention for their potential to improve early cancer detection and monitoring.

Cancer Biomarkers Market- Market Dynamics

Rising Demand for Personalized Medicine Fuels Growth in the Cancer Biomarkers Market

Rising demand for personalized medicine is significantly driving the growth of the Cancer Biomarkers Market as it allows for more targeted and effective cancer treatments. Organizations like the National Institutes of Health (NIH) and the World Health Organization (WHO) emphasize the importance of biomarkers in advancing precision oncology, especially with global cancer cases expected to rise by 47% between 2020 and 2040. For instance, the American Cancer Society has highlighted how biomarkers such as BRCA1 and BRCA2 are pivotal in assessing breast and ovarian cancer risks. Additionally, biomarker-driven therapies are increasingly being incorporated into clinical guidelines, as seen in the U.S. FDA's approval of multiple biomarker-based treatments over the past decade. These advancements are propelling research and innovation in cancer diagnostics and treatment pathways.

Cancer Biomarkers Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 12.90% over the forecast period (2024-2032)

Based on Biomarker Type segmentation, Genetic biomarkers were predicted to show maximum market share in the year 2023

Based on Cancer Type segmentation, Breast cancer was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Cancer Biomarkers Market- Segmentation Analysis:

The Global Cancer Biomarkers Market is segmented on the basis of Biomarker Type, Cancer Type, Application, and Region.

The market is divided into four categories based on Biomarker Type: Genetic Biomarkers, Protein Biomarkers, Epigenetic Biomarkers, and Metabolic Biomarkers. Genetic biomarkers hold the highest priority due to their critical role in cancer diagnosis and personalized therapies. Protein biomarkers follow, essential for monitoring disease progression. Epigenetic and metabolic biomarkers are gaining importance but rank slightly lower in clinical applications.

The market is divided into two categories based on Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, and Prostate Cancer. Breast cancer biomarkers take top priority due to high incidence and extensive research. Lung cancer follows closely, given its mortality rate and biomarker advancements. Colorectal cancer ranks third, with increasing diagnostic focus, while prostate cancer biomarkers hold slightly lower priority in the market.

Cancer Biomarkers Market- Geographical Insights

North America dominates the Cancer Biomarkers Market, driven by advanced healthcare infrastructure and significant R&D investments in precision medicine. The U.S. leads the region, with the National Cancer Institute (NCI) funding multiple biomarker research programs, contributing to around 1.9 million new cancer cases in 2021. Europe follows closely, where initiatives like the European Union's Horizon 2020 program have allocated substantial funding for biomarker-driven cancer research, particularly in the UK and Germany. In the Asia-Pacific region, rapid healthcare advancements and increasing cancer prevalence, notably in China and India, are fueling market growth. China's National Cancer Center reported over 4.5 million new cancer cases annually, prompting the government to invest in biomarker development. Latin America and the Middle East & Africa are emerging regions, with increasing awareness and government initiatives like Brazil's National Cancer Institute efforts in early diagnosis and biomarker adoption. These geographical dynamics reflect the varied focus and development of the cancer biomarkers market globally.

Cancer Biomarkers Market- Competitive Landscape:

The Cancer Biomarkers Market's competitive landscape is highly dynamic, with North America leading due to the presence of major players and frequent innovations. Companies like Thermo Fisher Scientific and Roche Diagnostics dominate the region, with Roche recently launching its Elecsys(R) PD-L1 biomarker test, enhancing its oncology diagnostics portfolio. In Europe, Qiagen and Bio-Rad Laboratories are key players driving the market with strategic collaborations. For instance, in 2022, Qiagen collaborated with Neuron23 to develop companion diagnostics for neurodegenerative diseases, expanding its focus on biomarker-based therapies. The Asia-Pacific region is witnessing rising competition, with companies like China's BGI Genomics entering international partnerships to leverage biomarker research. In 2021, India-based Strand Life Sciences was acquired by Quest Diagnostics to bolster its oncology testing capabilities. Latin America and the Middle East & Africa are still developing, but growing partnerships and investments indicate a rising interest in biomarker-based cancer solutions, with companies focusing on expanding their presence in these regions.

Recent Developments:

In August 2024, Illumina's TruSight Oncology Comprehensive test received FDA approval as the first comprehensive genomic profiling IVD kit for cancer. It profiles over 500 genes, aiding in targeted therapy matching for patients with specific solid tumors and gene fusions.

In October 2024, AstraZeneca plans to launch biomarker-driven therapies as alternatives to traditional chemotherapy. The company aims to enhance patient outcomes by focusing on precision medicine, targeting specific cancer types with tailored treatments based on genetic markers and tumor characteristics.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CANCER BIOMARKERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Exact Sciences Corporation
  • Foundation Medicine, Inc. (Roche)
  • GE Healthcare (General Electric Company)
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • NeoGenomics, Inc.
  • PerkinElmer, Inc.
  • Qiagen N.V.
  • Roche Diagnostics (F. Hoffmann-La Roche AG)
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Others

GLOBAL CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE- MARKET ANALYSIS, 2019 - 2032

  • Genetic Biomarkers
  • Protein Biomarkers
  • Epigenetic Biomarkers
  • Metabolic Biomarkers

GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE- MARKET ANALYSIS, 2019 - 2032

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer

GLOBAL CANCER BIOMARKERS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Diagnosis
  • Prognosis
  • Drug Discovery and Development
  • Personalized Medicine

GLOBAL CANCER BIOMARKERS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Cancer Biomarkers Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Cancer Biomarkers Market Snippet by Biomarker Type
    • 2.1.2. Cancer Biomarkers Market Snippet by Cancer Type
    • 2.1.3. Cancer Biomarkers Market Snippet by Application
    • 2.1.4. Cancer Biomarkers Market Snippet by Country
    • 2.1.5. Cancer Biomarkers Market Snippet by Region
  • 2.2. Competitive Insights

3. Cancer Biomarkers Key Market Trends

  • 3.1. Cancer Biomarkers Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Cancer Biomarkers Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Cancer Biomarkers Market Opportunities
  • 3.4. Cancer Biomarkers Market Future Trends

4. Cancer Biomarkers Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Cancer Biomarkers Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Cancer Biomarkers Market Landscape

  • 6.1. Cancer Biomarkers Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Cancer Biomarkers Market - By Biomarker Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Biomarker Type, 2023 & 2032 (%)
    • 7.1.2. Genetic Biomarkers
    • 7.1.3. Protein Biomarkers
    • 7.1.4. Epigenetic Biomarkers
    • 7.1.5. Metabolic Biomarkers

8. Cancer Biomarkers Market - By Cancer Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Cancer Type, 2023 & 2032 (%)
    • 8.1.2. Breast Cancer
    • 8.1.3. Lung Cancer
    • 8.1.4. Colorectal Cancer
    • 8.1.5. Prostate Cancer

9. Cancer Biomarkers Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 9.1.2. Diagnosis
    • 9.1.3. Prognosis
    • 9.1.4. Drug Discovery and Development
    • 9.1.5. Personalized Medicine

10. Cancer Biomarkers Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Cancer Biomarkers Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Cancer Biomarkers Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Cancer Biomarkers Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Cancer Biomarkers Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Cancer Biomarkers Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Cancer Biomarkers Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Abbott Laboratories
    • 11.2.2. Agilent Technologies, Inc.
    • 11.2.3. Bio-Rad Laboratories, Inc.
    • 11.2.4. Exact Sciences Corporation
    • 11.2.5. Foundation Medicine, Inc. (Roche)
    • 11.2.6. GE Healthcare (General Electric Company)
    • 11.2.7. Guardant Health, Inc.
    • 11.2.8. Hologic, Inc.
    • 11.2.9. Illumina, Inc.
    • 11.2.10. Myriad Genetics, Inc.
    • 11.2.11. NeoGenomics, Inc.
    • 11.2.12. PerkinElmer, Inc.
    • 11.2.13. Qiagen N.V.
    • 11.2.14. Roche Diagnostics (F. Hoffmann-La Roche AG)
    • 11.2.15. Siemens Healthineers AG
    • 11.2.16. Thermo Fisher Scientific Inc.
    • 11.2.17. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us